Cambium Bio Ltd
CMB
Company Profile
Business description
Cambium Bio Ltd is a clinical-stage regenerative medicine company in Australia. It focuses on the development of biologics for ophthalmology and tissue repair applications. Its technology platform is based on human platelet lysate, which is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. The company's product candidate Elate Ocular is being developed to address unmet medical needs in the treatment of dry eye disease. In addition, its stem cell platform, Progenza, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications.
Contact
16 Goodhope Street
Paddington
SydneyNSW2021
AUST: +61 1300995098
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
Stocks News & Analysis
stocks
Anglo American strikes deal to create a new copper giant
We are surprised that Teck agreed to the merger on these terms, and wouldn’t be surprised if there is a twist in the tale.
stocks
The ‘other’ AI chip behemoth that might just be getting started
The magnitude of growth at Broadcom continues to astound us.
stocks
Why ANZ changes aren’t just about cutting costs
The banking major needs to prevent key product offerings from falling further behind the competition.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,075.00 | 5.50 | -0.06% |
| CAC 40 | 7,761.32 | 11.93 | 0.15% |
| DAX 40 | 23,632.95 | 85.50 | -0.36% |
| Dow JONES (US) | 45,490.92 | 220.42 | -0.48% |
| FTSE 100 | 9,225.39 | 17.14 | -0.19% |
| HKSE | 26,200.26 | 262.13 | 1.01% |
| NASDAQ | 21,886.06 | 6.57 | 0.03% |
| Nikkei 225 | 44,084.98 | 247.31 | 0.56% |
| NZX 50 Index | 13,195.38 | 80.86 | -0.61% |
| S&P 500 | 6,532.04 | 19.43 | 0.30% |
| S&P/ASX 200 | 8,808.40 | 5.40 | -0.06% |
| SSE Composite Index | 3,812.22 | 4.93 | 0.13% |